Short Interest in Theravance Biopharma, Inc. (NASDAQ:TBPH) Declines By 58.9%

Theravance Biopharma, Inc. (NASDAQ:TBPH) was the recipient of a significant decrease in short interest during the month of August. As of August 14th, there was short interest totaling 1,714,947 shares, a decrease of 58.9% from the July 30th total of 4,168,511 shares. Approximately 3.6% of the company’s shares are sold short. Based on an average trading volume of 683,553 shares, the short-interest ratio is presently 2.5 days.

Analyst Upgrades and Downgrades

A number of brokerages recently commented on TBPH. HC Wainwright downgraded Theravance Biopharma from a “buy” rating to a “neutral” rating and upped their target price for the company from $15.00 to $17.00 in a report on Tuesday, July 7th. BTIG Research lowered shares of Theravance Biopharma from a “buy” rating to a “neutral” rating in a report on Monday, June 29th. Wall Street Zen cut Theravance Biopharma from a “buy” rating to a “hold” rating in a research report on Saturday, May 16th. JonesTrading downgraded Theravance Biopharma from a “buy” rating to a “hold” rating in a report on Monday, June 29th. Finally, Weiss Ratings raised Theravance Biopharma from a “hold (c)” rating to a “hold (c+)” rating in a research report on Monday, August 17th. One research analyst has rated the stock with a Strong Buy rating and seven have assigned a Hold rating to the company. According to MarketBeat, Theravance Biopharma presently has a consensus rating of “Hold” and an average price target of $19.40.

Theravance Biopharma Price Performance

Shares of NASDAQ TBPH opened at $17.04 on Friday. Theravance Biopharma has a 1 year low of $13.08 and a 1 year high of $21.03. The stock has a market cap of $884.72 million, a P/E ratio of 16.87 and a beta of 0.19. The firm has a 50-day moving average of $16.95 and a 200 day moving average of $16.62.

Theravance Biopharma (NASDAQ:TBPH) last posted its quarterly earnings data on Monday, August 10th. The biopharmaceutical company reported ($0.11) EPS for the quarter, missing the consensus estimate of $0.07 by ($0.18). The business had revenue of $20.73 million for the quarter, compared to the consensus estimate of $22.49 million. Theravance Biopharma had a negative return on equity of 0.77% and a net margin of 51.58%. Research analysts expect that Theravance Biopharma will post 1.56 earnings per share for the current fiscal year.

Insider Transactions at Theravance Biopharma

In other Theravance Biopharma news, major shareholder Eli Samaha sold 37,799 shares of the stock in a transaction that occurred on Wednesday, July 1st. The stock was sold at an average price of $17.00, for a total value of $642,583.00. Following the completion of the sale, the insider owned 9,174,453 shares in the company, valued at approximately $155,965,701. This trade represents a 0.41% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, SVP Rhonda Farnum sold 13,314 shares of Theravance Biopharma stock in a transaction that occurred on Monday, June 15th. The stock was sold at an average price of $16.39, for a total value of $218,216.46. Following the completion of the sale, the senior vice president owned 232,457 shares in the company, valued at approximately $3,809,970.23. This represents a 5.42% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders have sold 350,011 shares of company stock valued at $6,008,309. 7.65% of the stock is currently owned by company insiders.

Institutional Trading of Theravance Biopharma

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Vanguard Group Inc. raised its stake in Theravance Biopharma by 2.5% during the third quarter. Vanguard Group Inc. now owns 2,211,582 shares of the biopharmaceutical company’s stock valued at $32,289,000 after buying an additional 54,152 shares during the last quarter. State Street Corp boosted its holdings in Theravance Biopharma by 4.4% in the fourth quarter. State Street Corp now owns 1,101,892 shares of the biopharmaceutical company’s stock worth $20,616,000 after acquiring an additional 45,987 shares in the last quarter. Dimensional Fund Advisors LP grew its stake in shares of Theravance Biopharma by 14.5% in the first quarter. Dimensional Fund Advisors LP now owns 983,615 shares of the biopharmaceutical company’s stock worth $15,960,000 after acquiring an additional 124,658 shares during the last quarter. Geode Capital Management LLC grew its stake in shares of Theravance Biopharma by 4.5% in the fourth quarter. Geode Capital Management LLC now owns 938,724 shares of the biopharmaceutical company’s stock worth $17,567,000 after acquiring an additional 40,734 shares during the last quarter. Finally, Arrowstreet Capital Limited Partnership bought a new position in shares of Theravance Biopharma during the third quarter valued at $10,611,000. Hedge funds and other institutional investors own 99.10% of the company’s stock.

Theravance Biopharma Company Profile

Theravance Biopharma is a biopharmaceutical company focused on the discovery, development and commercialization of innovative medicines, primarily in the areas of respiratory disease, inflammatory and immunology, and rare disorders. The company develops small-molecule therapies designed to address unmet medical needs by targeting specific molecular pathways. Its lead marketed product, YUPELRI® (revefenacin) inhalation solution, is the first and only once-daily, long-acting muscarinic antagonist (LAMA) approved by the U.S.